1932

Abstract

Fibrogenic lung reactions occur as a common phenotype shared among disorders of heterogeneous etiologies. Even with a common etiology, the extent and pattern of fibrosis vary greatly among individuals, even within families, suggesting complex gene-environment interactions. The search for mechanisms shared among all fibrotic lung diseases would represent a major advance in the identification of therapeutic targets that could have a broad impact on lung health. Although it is difficult to grasp all of the complexities of the varied cell types and cytokine networks involved in lung fibrogenic responses, and to predict the biologic responses to the overexpression or deficiency of individual cytokines, a large body of evidence converges on a single common theme: the central importance of the transforming growth factor beta (TGF-β) pathway. Therapies that act upstream or downstream of TGF-β activation have the therapeutic potential to treat all fibrogenic responses in the lung.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.pathol.4.110807.092217
2010-02-28
2024-12-03
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.pathol.4.110807.092217
Loading
/content/journals/10.1146/annurev.pathol.4.110807.092217
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error